Serenex, Inc., a leader in the discovery and development of small molecule Heat Shock Protein 90 (Hsp90) inhibitors, today announced the signing of a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI). Under this CTA, Dr.

BALTIMORE, July 13 /PRNewswire/ -- BioFortis announced today that the National Cancer Institute (NCI) at the National Institutes of Health has selected its software, Labmatrix(TM), for use within its Center for Cancer Research (CCR).